[A26-05] Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2026
Project no.:
A26-05
Commission:
Commission awarded on 14.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
Result of dossier assessment:
- Patients with tumour cell PD-L1 expression ≥ 1% or a combined positive score ≥ 10; first-line treatment: added benefit not proven
- Patients with no tumour cell PD-L1 expression ≥ 1% and no combined positive score ≥ 10; first-line treatment: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-05
| Project no. | Title | Status |
|---|---|---|
| A26-04 | Toripalimab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |